id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-4590-0007,FDA,FDA-2016-E-4590,Determination of Regulatory Review Period for Purposes of Patent Extension; XTAMPZA ER,Notice,Determinations,2024-12-30T05:00:00Z,2024,12,2024-12-30T05:00:00Z,2025-03-01T04:59:59Z,2024-12-30T17:07:31Z,2024-31023,0,0,0900006486894b76
FDA-2016-E-4590-0006,FDA,FDA-2016-E-4590,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2024-12-19T05:00:00Z,2024,12,2024-12-19T05:00:00Z,,2024-12-19T13:28:53Z,,0,0,090000648687e050
FDA-2016-E-4590-0005,FDA,FDA-2016-E-4590,Requirement for Information,Other,Letter(s),2024-04-10T04:00:00Z,2024,4,2024-04-10T04:00:00Z,,2024-04-10T16:33:38Z,,0,0,09000064864c1954
FDA-2016-E-4590-0004,FDA,FDA-2016-E-4590,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-22T04:00:00Z,2024,3,2024-03-22T04:00:00Z,,2024-03-22T18:18:49Z,,0,0,090000648648d31e